摘要
目的探讨胃癌患者血清miR-106a表达及其与临床病理特征之间的关系。方法采用实时定量RT-PCR方法检测21例胃癌患者及10例健康人血清中miR-106a表达的水平。结果实时定量RT-PCR方法能够检测到血清样本中微量miRNA的表达。21例胃癌患者miR-106a表达水平的中位数为0.34(0.17~0.69),10例健康人为0.63(0.27~1.0),两者差异有统计学意义(P=0.002)。在21例胃癌患者中,血清miR-106a表达水平与肿瘤分化程度有关,在低分化胃癌中的表达水平明显高于中分化胃癌(P=0.01);血清miR-106a表达水平亦与血清CA724相关(P=0.03),而与分期、性别、年龄无关(P>0.05)。结论采用实时定量RT-PCR方法检测血清中miR-106a的表达敏感可靠。血清miR-106a作为新的生物学指标对于胃癌的诊断具有一定的价值。
Objective To investigate the expression level of miR-106a in serum of patients with gastric cancer and its clinical significance. Methods Real-time quantitative RT-PCR (qRT-PCR) was performed in serum of 21 gastric cancer patients and 10 normal controls. Results Small amount of miR-lO6a was detected in serum using a qRT-PCR platform. The median expression level of miR-106a was 0. 34(0. 17-0. 69)in 21 gastric cancer patients and 0. 63(0. 27-1.0)in 10 normal controls. Serum miR-106a expression level in 21 patients was significantly lower than that in normal controls (P = 0. 002). Serum miR-106a expression was significantly associated with tumor differentiation( P =0. 01 ) and serum CA724( P = 0. 03 ). No correlation was found between serum miR-106a expression level and tumor stage, sex or age ( P 〉 0.05 ). Conclusion The qRT-PCR assay is reliable and sensitive for detecting the expression of miR-106a. Our data confirm a role for serum miR-106a as a novel cancer biomarker in gastric cancer.
出处
《临床肿瘤学杂志》
CAS
2012年第6期485-489,共5页
Chinese Clinical Oncology
基金
苏州市科技发展基金(SZD09127)
南京医科大学科技发展基金面上项目(NMU069)